Multiple sclerosis is a devastating disease of the central nervous system that mainly affects young adults, with a 3:1 ratio of women to men. Fortunately, in the last 10 years, biotherapies with a significant impact on the disease relapse rate have become available. By 2014, three new drugs will have been approved in France, making a total of 12 drugs. Each drug has a different mechanism of action. Unfortunately, any criterion for choosing a drug is linked to its action.
So it is possible to imagine rationalizing treatment choice on the basis of biological information associated with the disease pathogenesis.
On the other hand, severe adverse events have been found to be associated with almost all drugs. If biological markers could help us define a subgroup of patients with a higher risk of severe adverse event, in the context of a large choice of treatment, some patients could be advised not to use a particular drug.